Hosted on MSN20d
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
Which Medical Stock Will Win The Battle For Supremacy? Roche and Zealand Pharma agreed to co-develop and co-commercialize petrelintide as a single drug and in a combination with Roche's CT-388. Roche ...
pharmaphorum10mon
Roche trumpets potential ‘best-in-class’ obesity drug
Roche has reported early clinical data with its candidate obesity therapy CT-388, bought as part of its $3.1 billion takeover of Carmot Therapeutics that was announced last year. A phase 1b trial ...
Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
Wall Street Journal21d
Roche Agrees to Develop Weight-Loss Therapy With Zealand Pharma
Roche Holding agreed a collaboration and licensing deal with Zealand Pharma to co-develop a weight-loss treatment using its ...
PMLiVE21d
Roche and Zealand partner on mid-stage obesity candidate in deal worth $5.3bn
The exclusive collaboration and licensing agreement will see the companies co-develop and co-commercialise the long-acting amylin analog as both a standalone therapy and as a fixed-dose combination ...
Morningstar21d
Roche: Collaboration With Zealand Adds Depth to Obesity Strategy
Why it matters: Roche entered the obesity landscape with the $2.7 billion acquisition of Carmot in early 2024, giving the firm access to development-stage candidates, including CT-388 and oral ...